EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Nathaniel M Schuster iD, Mark S Wallace, Thomas D Marcotte, Dawn C Buse, Euyhyun Lee, Lin Liu, Michelle Sexton

Headache: The Journal of Head and Face Pain · 2026-02 · 66 (2) · 365-376

DOI: 10.1111/head.70025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 30.12.2025. Verfasst von Nathaniel M Schuster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pain Management, Department of Anesthesiology, University of California San Diego Health System, La Jolla, California, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Cannabidiol, Dronabinol, Medical Marijuana. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCCIH NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the efficacy of cannabis for the treatment of acute migraine.

Background

Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.

Methods

In this randomized, double‐blind, placebo‐controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9‐tetrahydrocannabinol (THC) (THC‐dominant), (2) 11% cannabidiol (CBD) (CBD‐dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pain freedom and most bothersome symptom freedom, all assessed at 2‐h post‐vaporization.

Results

Ninety‐two participants were enrolled and randomized, and 247 migraine attacks were treated. THC + CBD was superior to placebo at achieving pain relief (67.2% vs. 46.6%, odds ratio [95% confidence interval] 2.85 [1.22, 6.65], p = 0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p = 0.017), and most bothersome symptom freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p = 0.005) at 2 h, as well as sustained pain freedom at 24 h and sustained most bothersome symptom freedom at 24 and 48 h. THC‐dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p = 0.008) but not pain freedom or most bothersome symptom freedom at 2 h. CBD‐dominant was not superior to placebo for pain relief, pain freedom, or most bothersome symptom freedom at 2 h. There were no serious adverse events.

Conclusion

Acute migraine treatment with 6% THC + 11% CBD was superior to placebo at 2‐h post‐treatment with sustained benefits at 24 and 48 h.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCannabidiolDronabinolMedical MarijuanaHumansDouble-Blind MethodCross-Over StudiesMaleAdultFemaleMiddle AgedYoung AdultTreatment OutcomeAcute Disease

Stichwörter der Autor:innen

acutecannabidiolcannabinoidscannabismigraineΔ9‐tetrahydrocannabinol

Substanzen

CannabidiolDronabinolMedical Marijuana

Autor:innen und Institutionen

  • Center for Pain Management, Department of Anesthesiology, University of California San Diego Health System, La Jolla, California, USA.
  • Center for Medicinal Cannabis Research, University of California San Diego Health System, San Diego, California, USA.
  • Department of Psychiatry, University of California San Diego Health System, San Diego, California, USA.
  • Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, USA.
  • Department of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Nathaniel M Schuster

Förderung

  • NINDS NIH HHS
  • NCCIH NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • Migraine Research Foundation
  • Academic Senate, University of California, San Diego
  • Academic Senate, University of California, Riverside
  • National Institutes of Health

Zitieren

APA

Schuster, N. M., Wallace, M. S., Marcotte, T. D., Buse, D. C., Lee, E., Liu, L., & Sexton, M. (2026). Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial. Headache: The Journal of Head and Face Pain, 66(2), 365-376. https://doi.org/10.1111/head.70025

Vancouver

Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L, et al. Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial. Headache: The Journal of Head and Face Pain. 2026;66(2):365-376. doi:10.1111/head.70025

BibTeX
@article{Schuster2026,
  author = {Schuster, Nathaniel M and Wallace, Mark S and Marcotte, Thomas D and Buse, Dawn C and Lee, Euyhyun and Liu, Lin and Sexton, Michelle},
  title = {Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {2},
  pages = {365--376},
  doi = {10.1111/head.70025}
}
Kostenlos starten →